Candel Therapeutics, Inc.(CADL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CADL Candel Therapeutics, Inc.

Market Closed 06-12 16:00:00 EDT

8.56

+0.40

+4.90%

盘后8.46

-0.10-1.11%

17:56 EDT

High8.72	Low8.16	Vol1.36M
Open8.23	D1 Closing8.16	Amplitude6.80%
Mkt Cap626.97M	Tradable Cap389.30M	Total Shares73.24M
T/O11.60M	T/O Rate2.99%	Tradable Shares45.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CADL","market":"US","secType":"STK","nameCN":"Candel Therapeutics, Inc.","latestPrice":8.56,"timestamp":1781294400000,"preClose":8.16,"halted":0,"volume":1361836,"hourTrading":{"tag":"盘后","latestPrice":8.4647,"preClose":8.56,"latestTime":"17:56 EDT","volume":428,"amount":3643.994,"timestamp":1781301364192,"change":-0.0953,"changeRate":-0.011133,"amplitude":0.011133},"delay":0,"changeRate":0.049019607843137296,"floatShares":45478500,"shares":73244500,"eps":-0.973062,"marketStatus":"Market Closed","change":0.4,"latestTime":"06-12 16:00:00 EDT","open":8.23,"high":8.715,"low":8.16,"amount":11602052.85512,"amplitude":0.068015,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.973062,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1781510400000},"marketStatusCode":7,"adr":0,"listingDate":1627358400000,"exchange":"NASDAQ","adjPreClose":8.16,"preHourTrading":{"tag":"盘前","latestPrice":8.36,"preClose":8.16,"latestTime":"09:19 EDT","volume":5524,"amount":45438.949092,"timestamp":1781270351860,"change":0.2,"changeRate":0.02451,"amplitude":0.061863},"postHourTrading":{"tag":"盘后","latestPrice":8.4647,"preClose":8.56,"latestTime":"17:56 EDT","volume":428,"amount":3643.994,"timestamp":1781301364192,"change":-0.0953,"changeRate":-0.011133,"amplitude":0.011133},"volumeRatio":0.7914366700012014,"impliedVol":0.9287,"impliedVolPercentile":0.3984},"requestUrl":"/m/hq/s/CADL","defaultTab":"news","newsList":[{"id":"2640942768","title":"Analyst Reiterates Buy Rating on Strengthened Phase 3 Data for Aglatimagene Besadenovec, Maintains $23 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2640942768","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640942768?lang=en_us&edition=fundamental","pubTime":"2026-06-03 00:45","pubTimestamp":1780418739,"startTime":"0","endTime":"0","summary":"In a report released today, Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on Candel Therapeutics, with a price target of $23.00....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-rating-on-strengthened-phase-3-data-for-aglatimagene-besadenovec-maintains-23-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-rating-on-strengthened-phase-3-data-for-aglatimagene-besadenovec-maintains-23-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CADL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640054949","title":"Candel Therapeutics publishes pivotal Phase 3 data for Aglatimagene","url":"https://stock-news.laohu8.com/highlight/detail?id=2640054949","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640054949?lang=en_us&edition=fundamental","pubTime":"2026-06-02 22:27","pubTimestamp":1780410443,"startTime":"0","endTime":"0","summary":"Candel Therapeutics (CADL) announced the publication of results from its pivotal Phase 3 trial of Aglatimagene in The Lancet Oncology. The trial, w...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/candel-therapeutics-publishes-pivotal-phase-3-data-for-aglatimagene-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/candel-therapeutics-publishes-pivotal-phase-3-data-for-aglatimagene-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","CADL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640948305","title":"Candel Therapeutics says Phase 3 trial shows 30% disease-free survival gain for CAN-2409 in localized prostate cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2640948305","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640948305?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:09","pubTimestamp":1780402174,"startTime":"0","endTime":"0","summary":"Candel Therapeutics flagged a peer-reviewed Lancet Oncology publication of pivotal Phase 3 results for CAN-2409 in localized prostate cancer.Results were previously disclosed in December 2024, with extended follow-up presented at the American Urological Association 2026 meeting.Trial outcome showed fewer disease recurrences when CAN-2409 was added to curative-intent radiotherapy versus radiotherapy alone.Safety profile remained broadly consistent with standard treatment, with no meaningful increase in clinically significant toxicity.Data are expected to underpin a planned biologics license application submission in Q4 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL3YTZRY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SG9999014021.USD","IE00BGHQF748.EUR","CADL","IE00BN0W2W23.USD","SG9999014039.USD","NDAQ","IE00BN0W2T93.GBP","LU2210149790.SGD","SG9999014013.SGD","BK4139","LU2210150020.SGD","SG9999014005.SGD","LU0314104364.USD","LU2095319765.USD","BK4539","BK4112","IE00BKPKM429.USD","IE00BN0W2V16.EUR","BK4585","IE00B3QW5Z07.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640943331","title":"Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2640943331","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640943331?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:05","pubTimestamp":1780401900,"startTime":"0","endTime":"0","summary":"Peer reviewed publication details pivotal data, demonstrating 30% improvement in disease-free survival (DFS) in patients with localized prostate cancer undergoing standard-of-care radiotherapy with cu","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/02/3305133/0/en/Candel-Therapeutics-Announces-Publication-in-The-Lancet-Oncology-of-Pivotal-Phase-3-Data-Demonstrating-Significant-Improvement-in-Disease-Free-Survival-with-Aglatimagene-Besadenove.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CADL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640964540","title":"Candel Therapeutics grants inducement stock options for 63,000 shares at $8.3 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2640964540","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640964540?lang=en_us&edition=fundamental","pubTime":"2026-06-02 04:08","pubTimestamp":1780344519,"startTime":"0","endTime":"0","summary":"Candel Therapeutics granted inducement stock options covering 63,000 shares to three new employees on May 31, 2026.Vesting schedule: 25% after one year from start date; remaining 75% vests monthly over the next 36 months.Awards were issued under the company’s 2025 Inducement Plan, adopted Dec. 24, 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL4D5JkG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","BK4585","IE00BN0W2W23.USD","NDAQ","SG9999014005.SGD","IE00BN0W2T93.GBP","BK4588","LU2095319765.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014021.USD","LU0314104364.USD","BK4139","BK4112","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","LU2210149790.SGD","BK4539","CADL","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640296412","title":"Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640296412","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640296412?lang=en_us&edition=fundamental","pubTime":"2026-06-02 04:05","pubTimestamp":1780344300,"startTime":"0","endTime":"0","summary":"NEEDHAM, Mass., June  01, 2026  (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immuno","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304707/0/en/Candel-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CADL","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640136984","title":"Bank of America Securities Remains a Hold on Candel Therapeutics (CADL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640136984","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640136984?lang=en_us&edition=fundamental","pubTime":"2026-06-01 09:19","pubTimestamp":1780276745,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Hold rating on Candel Therapeutics, with a price target...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-remains-a-hold-on-candel-therapeutics-cadl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-remains-a-hold-on-candel-therapeutics-cadl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4553","BK4504","LU0128525689.USD","LU0203345920.USD","LU0256863902.USD","IE00BZ1G4Q59.USD","LU1074936037.SGD","LU1267930227.SGD","LU1496350502.SGD","LU0314106906.USD","LU0971096721.USD","LU0211331839.USD","LU0477156953.USD","PGF","BAC","BK4582","LU1162221912.USD","CADL","LU1201861165.SGD","LU0149725797.USD","LU1894683348.USD","BK4539","LU1366192091.USD","IE00BKVL7J92.USD","LU1280957306.USD","BK4581","IE00B1BXHZ80.USD","IE00B7SZLL34.SGD","LU0477156797.USD","LU0980610538.SGD","LU0106831901.USD","IE00B19Z3B42.SGD","LU0098860793.USD","LU0683600562.USD","BK4585","LU0052756011.USD","LU2129689605.HKD","IE00B19Z3581.USD","IE0002270589.USD","LU1883839398.USD","BK4207","LU0130102774.USD","LU2265009873.SGD","LU1506573853.SGD","LU0640476718.USD","IE00BLSP4239.USD","LU1880398554.USD","LU0320765646.SGD","LU0648001328.SGD","LU1035773651.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636300636","title":"Candel Therapeutics price target raised to $9 from $7 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2636300636","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636300636?lang=en_us&edition=fundamental","pubTime":"2026-05-19 03:30","pubTimestamp":1779132609,"startTime":"0","endTime":"0","summary":"BofA analyst Alec Stranahan raised the firm’s price target on Candel Therapeutics (CADL) to $9 from $7 and keeps a Neutral rating on the shares. Ca...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/candel-therapeutics-price-target-raised-to-9-from-7-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/candel-therapeutics-price-target-raised-to-9-from-7-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635806055","title":"Candel Therapeutics Highlights Phase 3 Prostate Cancer Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2635806055","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635806055?lang=en_us&edition=fundamental","pubTime":"2026-05-16 06:08","pubTimestamp":1778882908,"startTime":"0","endTime":"0","summary":"Candel Therapeutics ( ($CADL) ) has provided an announcement. On May 15, 2026, Candel Therapeutics held a live investor webcast in conjunction with...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/candel-therapeutics-highlights-phase-3-prostate-cancer-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/candel-therapeutics-highlights-phase-3-prostate-cancer-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CADL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635968037","title":"Candel says CAN-2409 cuts prostate cancer recurrence risk 39% in Phase 3 follow-up","url":"https://stock-news.laohu8.com/highlight/detail?id=2635968037","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635968037?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:07","pubTimestamp":1778875637,"startTime":"0","endTime":"0","summary":"Candel Therapeutics disclosed extended follow-up results from its pivotal Phase 3 trial of CAN-2409 in intermediate- to high-risk localized prostate cancer, presented at AUA 2026.Prolonged follow-up continued to show fewer prostate cancer recurrences versus placebo when CAN-2409 was added to standard radiotherapy.Secondary readouts also favored CAN-2409, pointing to longer periods before disease progression and reduced spread, though most measures remained exploratory at this stage.Candel plans to submit a Biologics License Application to US FDA in Q4 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL2n7VJ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4139","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","NDAQ","SG9999014039.USD","LU2210150020.SGD","BK4539","LU2095319765.USD","LU0314104364.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","CADL","BK4585","SG9999014021.USD","LU2210149790.SGD","IE00BN0W2W23.USD","BK4588","BK4112","SG9999014005.SGD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635037502","title":"Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients From Phase 3 Trial of Aglatimagene Besadenovec (Can-2409) in Localized Prostate Cancer Under Prolonged Follow-up at Aua 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2635037502","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635037502?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:05","pubTimestamp":1778875500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nTUABQGYQN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635908037","title":"Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2635908037","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635908037?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:05","pubTimestamp":1778875500,"startTime":"0","endTime":"0","summary":"Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed a statistically significant and clinically meaningful improvement in prosta","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/15/3296125/0/en/Candel-Therapeutics-Reports-Extended-Clinical-Benefit-Over-Multiple-Clinical-Endpoints-in-Patients-from-Phase-3-Trial-of-Aglatimagene-Besadenovec-CAN-2409-in-Localized-Prostate-Can.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","BK4600","BK4166","LU0054578231.USD","BK4588","BK4099","LU1861217088.USD","LU1668664300.SGD","BK4585","BK4539","BK4170","BK4523","CADL","LU0106831901.USD","LU2360107671.USD","BK4139","LU0053671581.USD","LU1861220207.SGD","BK4121","BK4109","BK4595","BK4526","LU1791807156.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635089891","title":"Canaccord Genuity Reaffirms Their Buy Rating on Candel Therapeutics (CADL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635089891","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635089891?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:11","pubTimestamp":1778843515,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst John Newman maintained a Buy rating on Candel Therapeutics today and set a price target of $25.00. Newman covers the Heal...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-reaffirms-their-buy-rating-on-candel-therapeutics-cadl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-reaffirms-their-buy-rating-on-candel-therapeutics-cadl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635085553","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (HUM), Pyxis Oncology (PYXS) and Candel Therapeutics (CADL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635085553","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635085553?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:30","pubTimestamp":1778841020,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Humana (HUM), Pyxis Oncology (PYXS) and Candel The...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-humana-hum-pyxis-oncology-pyxs-and-candel-therapeutics-cadl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-humana-hum-pyxis-oncology-pyxs-and-candel-therapeutics-cadl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HUM","BK4585","LU0417517546.SGD","SG9999014005.SGD","LU0238689110.USD","BK4533","LU0208291251.USD","LU1983260115.SGD","LU0266013472.USD","BK4139","LU0390134368.USD","LU0070302665.USD","BK4137","LABU","LU0320765489.SGD","LU0348723411.USD","LU1093756325.SGD","XBI","BK4566","SG9999014013.SGD","HCSG","SG9999014021.USD","LU0170899867.USD","BK4588","LU0211331839.USD","BK4581","BK4539","XLV","LU0029874061.USD","LU0256863811.USD","LU0128526141.USD","PYXS","LU1093756168.USD","BK4154","CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635289267","title":"Candel Therapeutics publishes corporate presentation on viral immunotherapies for solid tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2635289267","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635289267?lang=en_us&edition=fundamental","pubTime":"2026-05-15 03:52","pubTimestamp":1778788369,"startTime":"0","endTime":"0","summary":"Candel Therapeutics investor presentation highlighted positive phase 3 data for lead candidate aglatimagene besadenovec  in localized, intermediate- to high-risk prostate cancer, with trial meeting primary endpoint of disease-free survival.Program also cited positive overall survival signals from randomized phase 2a studies in borderline resectable pancreatic cancer, with additional phase 2a overall survival data in therapy-resistant non-small cell lung cancer.Regulatory status includes FDA RMAT designation in prostate cancer, Fast Track designations in prostate, NSCLC, pancreatic cancer, with Orphan Drug designation in pancreatic cancer.Balance sheet snapshot showed cash and cash equivalents of $194.8 million as of March 31, 2026, with expected runway into Q1 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL1B8JXK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CADL","BK4139","TRIN","BK4539","BK4135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635749491","title":"Candel Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635749491","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635749491?lang=en_us&edition=fundamental","pubTime":"2026-05-14 23:36","pubTimestamp":1778773014,"startTime":"0","endTime":"0","summary":"Candel Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryCandel Therapeutics Inc CADL.OQ reported a quarterly adjusted loss of 14 cents per share for the quarter ended ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL8N41R1VK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635220712","title":"Candel Therapeutics reports Q1 loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2635220712","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635220712?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:15","pubTimestamp":1778760959,"startTime":"0","endTime":"0","summary":"Candel Therapeutics reports Q1 lossOverviewU.S. cancer immunotherapy developer posted Q1 net loss, reversing prior-year net profitCompany ended Q1 with $194.8 mln cash, expects runway into Q1 2028Outl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL1N41R0LD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CADL","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635971245","title":"Candel Therapeutics Q1 EPS $(0.14) Beats $(0.34) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635971245","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635971245?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:12","pubTimestamp":1778760738,"startTime":"0","endTime":"0","summary":"Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.34) by 58.82 percent. This is a 207.69 percent decrease over earnings of $0.13 per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52556803/candel-therapeutics-q1-eps-0-14-beats-0-34-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635126217","title":"BRIEF-Candel Therapeutics Q1 Net Income USD -8.861 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635126217","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635126217?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:05","pubTimestamp":1778760345,"startTime":"0","endTime":"0","summary":"BRIEF-Candel Therapeutics Q1 Net Income USD -8.861 Million\n\n\nMay 14 (Reuters) - Candel Therapeutics Q1 operating expenses USD 16.284 million.\n\nQ1 income from operations USD -16.284 million vs. IBES estimate USD -16.8 million\nQ1 basic EPS USD -0.14","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nPLXB499C6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","CADL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635771257","title":"Candel Therapeutics Q1 Operating Expenses USD 16.284 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635771257","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635771257?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:05","pubTimestamp":1778760300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nPLXB499C6:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","CADL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.candeltx.com","stockEarnings":[{"period":"1week","weight":0.0059},{"period":"1month","weight":-0.0425},{"period":"3month","weight":0.833},{"period":"6month","weight":0.348},{"period":"1year","weight":0.597},{"period":"ytd","weight":0.515}],"compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.12},{"period":"6month","weight":0.088},{"period":"1year","weight":0.2286},{"period":"ytd","weight":0.0877}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.056687},{"month":2,"riseRate":0.4,"avgChangeRate":0.052018},{"month":3,"riseRate":0.2,"avgChangeRate":-0.120448},{"month":4,"riseRate":0.4,"avgChangeRate":0.650234},{"month":5,"riseRate":1,"avgChangeRate":0.18781},{"month":6,"riseRate":0.2,"avgChangeRate":-0.129951},{"month":7,"riseRate":0.25,"avgChangeRate":0.011025},{"month":8,"riseRate":0.8,"avgChangeRate":0.068985},{"month":9,"riseRate":0.4,"avgChangeRate":-0.01705},{"month":10,"riseRate":0.4,"avgChangeRate":-0.110246},{"month":11,"riseRate":0,"avgChangeRate":-0.079739},{"month":12,"riseRate":0.8,"avgChangeRate":0.288433}],"exchange":"NASDAQ","name":"Candel Therapeutics, Inc.","nameEN":"Candel Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Candel Therapeutics, Inc.(CADL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Candel Therapeutics, Inc.(CADL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Candel Therapeutics, Inc.,CADL,Candel Therapeutics, Inc.股票,Candel Therapeutics, Inc.股票老虎,Candel Therapeutics, Inc.股票老虎国际,Candel Therapeutics, Inc.行情,Candel Therapeutics, Inc.股票行情,Candel Therapeutics, Inc.股价,Candel Therapeutics, Inc.股市,Candel Therapeutics, Inc.股票价格,Candel Therapeutics, Inc.股票交易,Candel Therapeutics, Inc.股票购买,Candel Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Candel Therapeutics, Inc.(CADL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Candel Therapeutics, Inc.(CADL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}